ACADIA Pharmaceuticals (FRA:DR6) Cyclically Adjusted Book per Share: €3.53 (As of Mar. 2026)


FRA:DR6 ACADIA Pharmaceuticals Inc FRA:DR6
76 GF Score
Price €22.60
GF Value €21.88
Valuation Fairly Valued
! 10 Warning Signs
View Full Analysis

What is ACADIA Pharmaceuticals Cyclically Adjusted Book per Share?

ACADIA Pharmaceuticals FRA:DR6 +1.48% 76 Cyclically Adjusted Book per Share is €3.53 as of Mar. 2026. GuruFocus rates FRA:DR6 with a GF Score™ of 76/100 and a GF Value™ of €21.88 (Fairly Valued). The stock has 10 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

ACADIA Pharmaceuticals's adjusted book value per share for the three months ended in Mar. 2026 was €6.310. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €3.53 for the trailing ten years ended in Mar. 2026.

During the past 12 months, ACADIA Pharmaceuticals's average Cyclically Adjusted Book Growth Rate was 10.10% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 3.90% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 7.30% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 9.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of ACADIA Pharmaceuticals was 17.20% per year. The lowest was 3.40% per year. And the median was 8.70% per year.

As of today (2026-07-05), ACADIA Pharmaceuticals's current stock price is €22.60. ACADIA Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was €3.53. ACADIA Pharmaceuticals's Cyclically Adjusted PB Ratio of today is 6.40.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of ACADIA Pharmaceuticals was 22.64. The lowest was 3.76. And the median was 7.64.


ACADIA Pharmaceuticals  (FRA:DR6) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

ACADIA Pharmaceuticals's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=22.60/3.53
=6.40

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of ACADIA Pharmaceuticals was 22.64. The lowest was 3.76. And the median was 7.64.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


ACADIA Pharmaceuticals Cyclically Adjusted Book per Share Related Terms


ACADIA Pharmaceuticals Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for ACADIA Pharmaceuticals's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ACADIA Pharmaceuticals Cyclically Adjusted Book per Share Chart

ACADIA Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.95 3.44 3.41 3.34 3.08

ACADIA Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.64 3.44 3.76 3.08 3.53

FRA:DR6 vs VKTX, EWTX, DNLI: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, ACADIA Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ACADIA Pharmaceuticals Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ACADIA Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where ACADIA Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


FRA:DR6
76GF Score
ACADIA Pharmaceuticals Inc FRA:DR6
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ACADIA Pharmaceuticals Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, ACADIA Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=6.31/330.2130*330.2130
=6.310

Current CPI (Mar. 2026) = 330.2130.

ACADIA Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201606 3.200 241.018 4.384
201609 4.253 241.428 5.817
201612 4.049 241.432 5.538
201703 3.507 243.801 4.750
201706 3.020 244.955 4.071
201709 2.580 246.819 3.452
201712 2.277 246.524 3.050
201803 1.977 249.554 2.616
201806 1.813 251.989 2.376
201809 1.532 252.439 2.004
201812 2.927 251.233 3.847
201903 2.569 254.202 3.337
201906 2.383 256.143 3.072
201909 4.076 256.759 5.242
201912 4.052 256.974 5.207
202003 3.717 258.115 4.755
202006 3.741 257.797 4.792
202009 3.500 260.280 4.440
202012 3.229 260.474 4.094
202103 3.050 264.877 3.802
202106 2.919 271.696 3.548
202109 2.999 274.310 3.610
202112 2.973 278.802 3.521
202203 2.503 287.504 2.875
202206 2.542 296.311 2.833
202209 2.656 296.808 2.955
202212 2.332 296.797 2.595
202303 2.153 301.836 2.355
202306 2.236 305.109 2.420
202309 2.070 307.789 2.221
202312 2.405 306.746 2.589
202403 2.588 312.332 2.736
202406 2.894 314.175 3.042
202409 3.126 315.301 3.274
202412 4.198 315.605 4.392
202503 4.236 319.799 4.374
202506 4.229 322.561 4.329
202509 4.620 324.800 4.697
202512 6.155 324.054 6.272
202603 6.310 330.213 6.310

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €3.53 mean?
ACADIA Pharmaceuticals (FRA:DR6) has a Cyclically Adjusted Book per Share of €3.53 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on ACADIA Pharmaceuticals and its competitors.
Is ACADIA Pharmaceuticals' Cyclically Adjusted Book per Share too high?
ACADIA Pharmaceuticals' current Cyclically Adjusted Book per Share is €3.53. Overall, ACADIA Pharmaceuticals has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does ACADIA Pharmaceuticals' Cyclically Adjusted Book per Share compare to VKTX and EWTX?
ACADIA Pharmaceuticals' Cyclically Adjusted Book per Share of €3.53 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on ACADIA Pharmaceuticals and its competitors. ACADIA Pharmaceuticals's current Cyclically Adjusted Book per Share is €3.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACADIA Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, ACADIA Pharmaceuticals (FRA:DR6) is currently considered Fairly Valued. The stock's GF Value™ is €21.88, compared to a current price of €22.60 — trading 3.3% above its estimated fair value. The current Cyclically Adjusted Book per Share is €3.53. ACADIA Pharmaceuticals' overall GF Score™ is 76/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For ACADIA Pharmaceuticals (FRA:DR6), the current Cyclically Adjusted Book per Share is €3.53 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ACADIA Pharmaceuticals (FRA:DR6) Overvalued in 2026?

Based on GuruFocus' analysis, ACADIA Pharmaceuticals stock appears to be overvalued. The current stock price of €22.60 is trading 3.3% above its estimated GF Value™ of €21.88. GuruFocus considers ACADIA Pharmaceuticals to be Fairly Valued.

Key valuation signals for FRA:DR6:

  • Cyclically Adjusted Book per Share: €3.53
  • GF Value™: €21.88 vs. price of €22.60 (3.3% above fair value)
  • GF Score™: 76/100 with 10 warning signs

No single metric tells the full story. See the FRA:DR6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


ACADIA Pharmaceuticals Business Description

Other Exchanges ACAD:USAACAD:Mexico
Address 12830 El Camino Real, Suite 400, San Diego, CA, USA, 92130
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-211, ACP-711, ACP-2591, etc.
76GF Score

Get the complete analysis for FRA:DR6

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€22.60
Price
€21.88
GF Value